Skip to content

GlucoSet vs Masimo

GlucoSet logo

GlucoSet

Intensive care monitoring

16 employees · est. 2011 · Norway

VS
Masimo logo

Masimo

Masimo innovations empower clinicians to transform patient care

3534 employees · est. 1989 · Irvine, United States

Masimo is the older company (2011 vs 1989); Masimo is the larger of the two.

Side-by-Side Comparison

GlucoSet Masimo
Founded
2011 1989 older
Headquarters
Norway Irvine, United States
Employees
16 3534 larger
Industry
Biotechnology, Health Care, Medical Devices Biotechnology, Health Care, Manufacturing
Funding Stage
Not tracked yet IPO
Total Funding
$8.50M $755.00M
Funding Rounds
5 5
Services
Continuous blood glucose monitoring devices, Minimally invasive sensor solutions, ICU cost reduction strategies, Glucose normalization technology Patient Monitoring Systems, Emergency Medical Services Solutions, Healthcare Automation, Remote Monitoring and Notification, Medical Device Integration, Clinical Analytics
Target Customers
Hospitals, Intensive Care Units, Healthcare Providers, Medical Professionals, Healthcare Systems Hospitals, Healthcare Professionals, Emergency Medical Services, ICU and NICU Facilities, Home Care Providers, Contract Research Organizations, Government and Military Healthcare Units
Taxonomy
Intensive Care UnitGlucose MonitoringIntravascular SensorsContinuous MonitoringBlood Glucose ControlPatient Outcomes +6 Medical TechnologyPatient MonitoringNoninvasive MonitoringHealthcare InnovationClinical Decision MakingPatient Safety +6
Website
glucoset.com masimo.com
GlucoSet logo

About GlucoSet

GlucoSet, founded in 2011 and headquartered in Norway, is poised to revolutionize the Intensive Care Unit (ICU) environment with its cutting-edge biotechnology solutions. The company operates in the Biotechnology, Health Care, and Medical Devices industries, focusing on addressing critical health ch...

Masimo logo

About Masimo

Masimo (NASDAQ: MASI), founded in 1989, is a pioneering force in the Biotechnology, Health Care, Manufacturing, and Medical Devices industries, with a focus on developing innovative noninvasive patient monitoring technologies. Based in the United States, the company is renowned for its clinically-pr...

Also comparing in this category

Comparing more than these two?

Get GlucoSet, Masimo and up to nine more competitors side by side in one PDF: team, funding, traffic and every dated move of the last six months. Every company is re-checked on the day you order.

How does GlucoSet compare?

A PDF of GlucoSet and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Rival Readout

Comparing competitors? We do this properly.

10 rivals, 90 days of dated moves in 7 business days: a ranked list of what matters, each with its source, ending in a 60-minute readout with your team.

Frequently Asked Questions

GlucoSet was founded in 2011, based in Norway, with 16 employees. GlucoSet, founded in 2011 and headquartered in Norway, is poised to revolutionize the Intensive Care Unit (ICU) environment with its cutting-edge biotechnology solutions. The company operates in the B. Masimo was founded in 1989, based in Irvine, United States, with 3,534 employees. Masimo (NASDAQ: MASI), founded in 1989, is a pioneering force in the Biotechnology, Health Care, Manufacturing, and Medical Devices industries, with a focus on developing innovative noninvasive patien.
GlucoSet has raised $8.50M and Masimo $755.00M. Latest stage: Masimo IPO.
Both work in Biotechnology, Health Care and Medical Devices and list patient safety among their focus areas.

Compare GlucoSet with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at GlucoSet on 6 Aug 2026, and Masimo on 11 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout